Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

Abstract

The most efficient therapeutic approach for immunoglobulin light chain amyloidosis (AL) is autologous stem cell transplantation (ASCT); however, the toxicity of ASCT limits its feasibility to a minority of patients. Patients ineligible for ASCT are usually treated with standard oral melphalan and prednisone, but the response rate to this regimen is unsatisfactory, and time to response is long. High-dose dexamethasone provides a rapid response time in patients with AL. We evaluated the combination of oral melphalan and high-dose dexamethasone (M-Dex) in 46 patients with AL ineligible for ASCT. Thirty-one (67%) achieved a hematologic response and 15 (33%) a complete remission. In 22 (48%) of the responsive patients functional improvement of the organs involved was observed. Five patients (11%) experienced severe adverse events, 3 required hospitalization, and no treatment-related deaths were observed. M-Dex represents a feasible and effective therapeutic option for patients with advanced AL who are ineligible for ASCT.

• Authors: Giovanni Palladini, Vittorio Perfetti, Laura Obici, Riccardo Caccialanza, Alessandra Semino, Fausto Adami, Giobatta Cavallero, Roberto Rustichelli, Giovambattista Virga, Giampaolo Merlini
• Journal: Blood (Blood) Vol. 103 Issue 8 Pg. 2936-8 (Apr 15 2004) ISSN: 0006-4971 [Print] United States
• PMID: 15070667 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Dexamethasone
• Melphalan

Topics

• Adult
• Aged
• Amyloidosis (drug therapy, therapy)
• Contraindications
• Dexamethasone (administration & dosage, adverse effects)
• Drug Therapy, Combination
• Drug Tolerance
• Female
• Humans
• Male
• Melphalan (administration & dosage, adverse effects)
• Middle Aged
• Stem Cell Transplantation